TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Present with mild AD dementia based on the National Institute on Aging (NIA) and the Alzheimer's Association (AA) disease diagnostic criteria as determined by a qualified clinician approved by the Sponsor or designee.~* Mini-Mental State Examination score of 20 to 26 inclusive at screening visit.~* Has a florbetapir PET scan consistent with the presence of amyloid pathology at screening.~Exclusion Criteria:~* Significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).~* Ocular pathology that significantly limits ability to reliably evaluate vision or the retina.~* Use of strong inducers of cytochrome P450 3A (CYP3A).~* Sensitivity to florbetapir or ¹⁸F-AV-1451.~* Contraindication to MRI or PET or poor venous access for blood draws.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dose 1 LY3202626 (Type: EXPERIMENTAL): 3 mg LY3202626 given orally once daily for 52 weeks.
- Dose 2 LY3202626 (Type: EXPERIMENTAL): 12 mg LY3202626 given orally once daily for 52 weeks.
- Placebo (Type: EXPERIMENTAL): Placebo given orally once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of an Anorectal Fistula Plug With Sealing of the Internal Opening as a Treatment for Perianal Fistula

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are psychologically stable and suitable for intervention and able to provide informed consent~  * Patients who are willing and competent to fill in questionnaires and undergo investigations at various time points during the study~ * Patients with an idiopathic extra and trans-sphincteric perianal fistula.~Exclusion Criteria:~* Patients aged less than 18 or \>80 years.~* Patients unfit to undergo general or spinal anaesthesia.~* Patients with a supra-levator fistula.~* Patients with a rectovaginal fistula.~* Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis).~* Patients with a fistula secondary to trauma, foreign body, developmental cyst or pelvic irradiation.~* Patients who are immunosuppressed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- investigational arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Diabetes Body Project Among Females With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, 16-35 years, type 1 diabetes, acknowledges at least some level of body image concerns~Exclusion Criteria:~* Other forms of diabetes, males

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Diabetes Body Project (Type: EXPERIMENTAL): Participants randomized to the experimental condition will receive virtual Diabetes Body Project groups immediately.
- Educational (Type: ACTIVE_COMPARATOR): Participants randomized to the control condition will receive an education brochure and will be offered the Diabetes Body Project after 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Induction Treatment Followed by Immunosuppression Withdrawal in Liver Transplantation: A Comparative Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Recipient of a primary liver graft~* Absence of any of our exclusion criteria~Exclusion Criteria:~* Pretransplant renal failure, defined as serum creatinine \> 1.5 mg/dL~* Severe pretransplant thrombopenia, defined as platelets \< 50000/mL~* Combined liver-kidney transplantation~* Autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis as causes of liver transplantation~* Chronic hepatic encephalopathy~* Living donor liver transplantation~* Recipient with human immunodeficiency virus infection~* Severe pretransplant leukopenia, defined as \< 1500 leukocytes/mL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Utility of Endothelial Dysfunction in PAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects age 21-99 years old.~2. Peripheral Arterial Disease. PAD is defined clinically and by angiography, magnetic resonance imaging, vascular ultrasound, or ankle brachial index less than 0.9.~3. Able to provide informed consent and complete the study procedure.~4. Patients undergoing non-emergent vascular surgery (peripheral arterial bypass, abdominal aortic aneurysm repair, carotid endarterectomy, or limb amputation) or other non-cardiac surgery.~Exclusion Criteria:~1. Emergent or urgent surgery that must be performed sooner than one week after enrollment~2. Unstable angina, myocardial infarction, stroke, coronary revascularization, or decompensated heart failure within 1 month of enrollment. Patients who require cardiac catheterization and surgical or percutaneous coronary revascularization prior to vascular surgery will be excluded.~3. Clinically evident major illness of other organ systems, including cancer, end-stage renal disease, hepatic failure, or other conditions that make participation inappropriate.~4. Women who are lactating, pregnant, or of childbearing potential and not using a reliable contraceptive method. Pregnancy will be excluded by a urine pregnancy test.~5. Patients with liver function tests or serum creatine kinase \>3 times the upper limit of normal.~6. Patients who have received an investigational drug within 30 days of enrollment.~7. Patients or subjects with a history of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.~8. Known occlusive atherosclerosis of the subclavian artery or upper extremity, because such disease will interfere with induction of reactive hyperemia during the brachial artery ultrasound studies.~9. Patients will be excluded if they are taking vitamin C in a dose greater than 2 times the Recommended Daily Allowance (\>120 mg/day) within 1 month of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): Atorvastatin 40 or 80 mg/day
- Ascorbic Acid (Type: EXPERIMENTAL): Ascorbic Acid 500 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo atorvastatin and Placebo ascorbic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18, ≤64 years~* Physician-diagnosis of asthma~* Regular inhaled budesonide (Giona Easyhaler, Pulmicort Turbuhaler, Novopulmon Novolizer or Symbicort Turbuhaler) treatment since at least 6 months~* Verified allergy to at least one airborne perennial allergen after objective testing (ImmunoCAP Rapid Asthma/Rhinitis Adult)~* ACQ \>1.0~* Can read and understand the Swedish language~* Written informed consent signed~Exclusion Criteria:~* Regular tobacco use within past 6 months~* ≥10 pack-years smoking history~* Keeping a furred pet at home~* Treatment with Singulair~* \>4 prednisolone courses last 12 months~* Ongoing pregnancy or lactation~* Participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: OTHER): Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
- Standard of care (Type: NO_INTERVENTION): Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults receiving cisplatin therapy in the dose range of 80-120mg/m2~2. Subjects are capable of giving informed consent, or if appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf.~Exclusion Criteria:~1. Subjects with active middle ear disease (unilateral or bilateral)~2. Subjects with prior treatment with platinum-based chemotherapeutic agent or other ototoxic agent~3. Subjects with an allergy to sodium thiosulfate~4. Subjects with tumors involving cranial nerve VIII~5. Subjects with preexisting absence of otoacoustic emissions (unilateral or bilateral)~6. Subjects with more than 5 dB interaural difference in puretone threshold on initial audiometric screening~7. Chronic use of known ototoxic agent (e.g. furosemide, aminoglycosides, etc)~8. Subjects with a history of prior irradiation to the head and neck.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Ear - Sodium Thiosulfate (STS) (Type: EXPERIMENTAL): Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
- Comparator Ear - Placebo (Type: PLACEBO_COMPARATOR): Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing panniculectomy in preparation for renal transplantation at the University of California Davis Medical Center. Patients who are entered into the trial and have 30 days of follow up, and those in the INPWT study arm who successfully complete 7 days of treatment, will be included.~Exclusion Criteria:~* All patients who previously demonstrated a hypersensitivity reaction to adhesives and qualify for panniculectomy in preparation for renal transplantation, or all patients who are undergoing panniculectomy for reasons other than in preparation for renal transplantation (i.e. after massive weight loss or for cosmetic reasons). Patients who do not complete the duration of treatment of negative pressure wound therapy (7 days), or patients who do not follow up for a minimum of 30 days from the date of surgery will be excluded. Adults unable to consent, infants, children, teenagers, pregnant patients and prisoners will be excluded. It is also extremely unlikely, based on our study population, that we will encounter any of these patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard Closure (Type: PLACEBO_COMPARATOR): After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
- Incisional Negative Pressure Wound Therapy (Type: ACTIVE_COMPARATOR): After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females 15-19 years of age~* Regular menstrual cycles of 22-35 days~* In general good health~* Medically approved birth control method if sexually active~* Evidence of ovulation~* Meeting all symptom criteria for PMS~* Signed informed consent~* Subjects under age 18 must also have signed parental consent~Exclusion Criteria:~* Current use of any treatment for PMS.~* Psychotropic or other medications that may compromise the study drug.~* Pregnancy, intending pregnancy or breast feeding.~* Not using a medically approved birth control method if sexually active.~* Significant medical or gynecological abnormalities.~* Irregular menses, any gynecologic disorder.~* Any severe or unstable medical illness.~* Any current major psychiatric diagnosis or any history of a major psychiatric diagnosis.~* Any current or history of alcohol abuse, drug abuse, suicide attempt, bi-polar disorder, psychosis or severe personality disorder.~* Use of triptans (Imitrex, Zomig, Frova, Maxalt, Axert, Amerge, Relpax).~* Use of medicines that include dextromethorphan such as Tylenol or Vicks cough medicines.~* Use of the pain medication meperidine.~* Use of any herbal product such as St John's Wort that may increase serotonin.~* Use of monoamine oxidase inhibitors (MAOIs), pimozide or citalopram hydrobromide.~* Drugs metabolized by CYP2D6 or a combination of CYP3A4 and CYP2D6 inhibitors.~* Hypersensitivity to escitalopram or citalopram.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram (Type: EXPERIMENTAL): Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
- placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matched to drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metformin and Congenital Nephrogenic Diabetes Insipidus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males with a documented mutation in the vasopressin type 2 receptor (V2R)~* Willing to provide consent and/or assent as appropriate~* Capable of providing urine samples as dictated by the protocol~Exclusion Criteria:~* Urinary incontinence~* Subjects who have heart disease, liver disease, diabetes, cancer, or other significant disease other than Nephrogenic Diabetes Insipidus (NDI)~* Subjects with significant renal dysfunction (defined as a calculated glomerular filtration rate (GFR) \<80 ml/min/1.73 m\^2)~* Subjects with acquired NDI

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of mild or moderate primary hypertension~* Be able to tolerate a 2 week washout phase followed by a 2 week Placebo run- in phase~* Be minimum 18 years of age~Exclusion Criteria:~* Be intolerant to alfa- or beta-blockers~* Have secondary causes of hypertension~* Be taking more than two antihypertensive medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Egalet carvedilol
- 2 (Type: ACTIVE_COMPARATOR): Coreg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Conservative Versus Surgical Management of Idiopathic Normal Pressure Hydrocephalus (INPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Normal pressure Hydrocephalus~Exclusion Criteria:~* Alzheimer disease~* Vascular dementia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open shunt (Type: ACTIVE_COMPARATOR): functioning shunt
- closed shunt (Type: ACTIVE_COMPARATOR): NON FUNCTIONING SHUNT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A clinical and histologic diagnosis of parapsoriasis (T0 CTCL)~* Age 18 years or older.~* Acceptable laboratory studies~* Must be free of serious concurrent illness.~* Women of child-bearing potential must have negative serum pregnancy test prior to the initiation of treatment.~Exclusion Criteria:~* Topical or systemic therapies within four weeks of entry in the study.~* Participation in any other investigational drug study within thirty days of entry in this study.~* Oral retinoid therapy for any indication within three months of entry in the study.~* Participation in any other study using topical retinoid therapy.~* Pregnancy or active breast-feeding.~* Serious known concurrent medical illness or infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ESP Volunteer LA Spread Controlled by MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers aged between 18 and 45 year old~Exclusion Criteria:~* Refusal of the volunteer~* Anatomical abnormalities of the thoracic spine identified by physical examination.~* Body mass index ≥30 kg/m2~* Medical contra-indication for Conscious MRI~* Claustrophobia~* Metal implants (pacemaker and others)~* Known allergy or hypersensitivity against Ropivacaine or other amino-amide LAs~* Participation in another clinical study within the last 4 weeks prior to study~* Coagulopathies in the medical history~* Abnormalities in electrocardiography that are considered clinically relevant such as atrio-ventricular block or bradycardia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Unilateral Erector spinae plane block (Type: EXPERIMENTAL): Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy